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Abstract
AIM: To determine whether -1195 A→G and/or -765 
G→C polymorphisms in Cyclooxygenase-2  (COX-2 ) 
may have a risk modifying effect on the development 
of esophageal carcinoma in a Dutch Caucasian 
population.
METHODS: Two study groups were recruited, 252 
patients with esophageal carcinoma and 240 healthy 
controls, matched for race, age, gender and recruiting 
area. DNA was isolated from whole blood and used 
for genotyping. PCR products were digested with 
restriction enzymes and products were analyzed by 
agarose gel electrophoresis. Odds ratios (OR) and 95% 
confidence intervals (CI) were estimated.
RESULTS: The distr ibut ion of the -1195 A→G 
polymorphism was significantly different in esophageal 
cancer patients compared to controls. The -1195 
GG genotype resulted in a higher risk of developing 
esophageal adenocarcinoma (OR = 3.85, 95% CI: 
1.45-10.3) compared with the -1195 AA genotype 
as a reference. The -765 G→C genotype distribution 
was not different between the two groups. The GG/
GG haplotype was present more often in esophageal 
adenocarcinoma patients than in controls (OR = 3.45, 
95% CI: 1.24-9.58; with AG/AG as a reference). The 
same trends were observed in patients with squamous 
cell carcinomas, however, the results did not reach 
statistical significance.
CONCLUSION: Presence of the COX-2 -1195 GG 
genotype and of the GG/GG haplotype may result in a 
higher risk of developing esophageal carcinoma. 
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
During the last few decades, the incidence of  esophageal 
carcinoma has sharply increased in Western-lifestyle 
countries. Two main types of  esophageal carcinoma exist, 
adenocarcinoma and squamous cell carcinoma. The main 
difference between adenocarcinoma and squamous cell 
carcinoma is the cell type from which the tumor originates; 
glandular or squamous epithelial cells, respectively.
Adenocarcinoma of  the esophagus predominantly 
occurs in Western societies. There is a strong and probably 
www.wjgnet.com
causal relation between gastro-esophageal reflux and the 
development of  esophageal adenocarcinoma[1]. Gastro-
esophageal reflux may cause damage to the esophageal 
tissue due to the high concentrations of  acid and bile 
salts, which may induce metaplasia and cell proliferation, 
thereby increasing the risk of  mutations. This can lead 
to Barrett’s esophagus with high grade dysplasia and 
ultimately to adenocarcinoma of  the esophagus[1,2].
In contrast to adenocarcinoma, squamous cell 
carcinoma of  the esophagus is thought to be caused 
predominantly by specific lifestyle or environmental 
factors such as heavy smoking in combination with 
alcohol use, chewing of  tobacco or consumption of  
spicy foods and hot beverages[3]. In certain developing 
countries such as China, India or Iran, squamous cell 
carcinoma of  the esophagus is very common, probably 
due to particular lifestyle habits[3]. As a result, damage 
to esophageal tissue may occur and tissue renewal may 
increase. This increased cell proliferation can lead to 
mutations, dysplasia and carcinoma. 
Cell proliferation may play a key role in tumor genesis 
and cyclooxygenases (COXs) are important regulatory 
enzymes in this process. COXs are enzymes that catalyze 
the conversion of  free arachidonic acid into prostaglandin 
H2, which is the precursor of  prostaglandins, prostacyclin 
and thromboxanes. These regulatory compounds play a 
role in many biological processes such as cell proliferation, 
angiogenesis, immune function and inflammation, which 
are all crucial in the development and progression of  
neoplasms[4]. The human COX family consists of  three 
members, COX-1-3[4,5]. COX-1 is found in most tissues 
and plays a role in homeostasis of  many physiologic 
processes. COX-3 is an alternative splice product of  
COX-1 and is believed to be involved in the regulation 
of  pain and fever. COX-2 is probably very important in 
the development and progression of  neoplasms. COX-2 
is an inducible enzyme whose expression can be induced 
by pro-inflammatory and mitogenic stimuli like cytokines 
and growth factors. COX-2 plays an important role in the 
development of  otherwise healthy tissue into metaplastic 
and dysplastic tissue, as well as in the development and 
progression of  a tumor, by taking part in the regulation 
of  cell proliferation, cell transformation, tumor growth, 
metastasis and invasion. COX-2 is often found over-
expressed in gastrointestinal tumors, including those of  
the esophagus[6-10]. Tumors which exhibit a high level of  
COX-2 seem to be more aggressive[6] and patients bearing 
those tumors showed a significantly reduced survival[10]. In 
addition, when COX-2 expression in laboratory animals 
was suppressed with medication, fewer animals developed 
esophageal adenocarcinoma[11]. Therefore, the role of  
COX-2 in the development of  normal or metaplastic 
tissue into neoplasms seems evident.
Recently, several functional Single Nucleotide 
Polymorphisms in the COX-2 gene have been discovered 
which may contribute to the variance in inter-individual 
COX-2 expression. The -1195 A→G substitution in 
the COX-2 promotor was found to be associated with a 
lower expression of  COX-2 in a Chinese population[12].
Another SNP, -765 G→C was first described in a UK 
population[13]. This polymorphism was shown to result 
in a lower promoter activity, which could subsequently 
lead to a lower expression of  COX-2.
The purpose of  this study is to determine the possible 
modulating effect of  the COX-2 polymorphisms -1195 A
→G and -765 G→C on the risk for developing esophageal 
cancer in a Dutch Caucasian population.
MATERIALS AND METHODS
Patients and controls
A group of  252 patients with esophageal carcinoma was 
recruited during the period October 2002 to January 
2008, in four hospitals all localized in the South-East 
area of  The Netherlands. These hospitals were: (1) 
Radboud University Nijmegen Medical Center, (2) 
Canisius Wilhelmina Hospital, Nijmegen, (3) Hospital 
Gelderse Vallei, Ede and (4) Rijnstate Hospital, Arnhem. 
Only patients with a diagnosis of  esophageal carcinoma 
as confirmed by a pathologist were included in the study. 
Following an advertisement in local papers, a group 
of  240 healthy controls was recruited from the same 
geographical area of  The Netherlands. Controls were 
matched with the esophageal carcinoma patients for age, 
ethnicity and gender. 
The study was approved in 2002 by the Medical 
Ethical Review Committee, region Arnhem-Nijmegen 
(CMO 2002/114). EDTA blood was collected from 
patients and controls. The whole blood samples were 
stored at -22℃ until use. DNA was extracted from 
whole blood by using the Puregene DNA Isolation Kit 
(Gentra Systems, Minneapolis, USA) according to the 
manufacturer’s instructions. The extracted DNA was 
stored at 4℃ until use. 
The extracted DNA was used for determination 
of  the -1195 A→G and -765 G→C polymorphisms in 
the COX-2 promoter by polymerase chain reaction/
restriction fragment length polymorphism (PCR/RFLP), 
exactly as described by Zhang et al[12]. 
Statistical analysis
The differences between characteristics of  patients with 
esophageal carcinoma and controls were analysed with the 
Student’s t-test. All genotypes of  controls and patients were 
tested to determine whether they were distributed according 
to the Hardy-Weinberg equilibrium. The chi-square test 
was used to test for differences in distribution of  genotypes 
between the two groups, or to estimate differences in allele 
frequencies. Odds ratios (OR) with 95% confidence interval 
(95% CI) were calculated for genotypes associated with 
predicted normal versus predicted altered enzyme activities 
(variant genotypes). COX-2 haplotypes were studied using 
the PL-EM software as described by Qin et al[14]. P < 0.05 
was considered to be statistically significant. All data were 
processed using SPSS software for Windows version 16.0 
(SPSS Inc, Chicago Illinois, USA).
RESULTS
Patients with esophageal carcinoma and controls were 
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matched for race, age, gender and recruiting area. Table 1 
shows the characteristics of  the patients and controls. The 
COX-2 genotype distributions in patients and controls are 
summarized in Table 2. The polymorphisms tested here 
were distributed according to the Hardy-Weinberg criteria, 
P-values in patients and controls were 0.98 and 0.47 for 
the -765 G→C polymorphism and 0.21 and 0.24 for the 
-1195 A→G polymorphism, respectively.
No significant differences in the distribution of  
the -765 G→C polymorphism between patients with 
esophageal carcinoma and controls were observed (P 
= 0.80; χ2 test). However, a significant difference in the 
distribution of  the -1195 A→G polymorphism between 
patients and controls was observed (P = 0.02; chi square 
test). The -1195 G/-1195 G genotype was present more 
often in patients with esophageal carcinoma (whole 
group) as compared to the -1195 A/-1195 A genotype in 
controls (OR 3.57, 95% CI 1.39-9.13, P = 0.005). When 
analyzed according to the type of  tumor, ORs were 3.85 
(95% CI 1.45-10.3) for patients with adenocarcinoma and 
3.29 (0.95-11.4) for patients with squamous cell carcinoma 
(Table 2). Allele frequencies in all patients with esophageal 
cancer (-1195 A vs -1195 G) also differed significantly 
from those in controls (P = 0.02). 
When comparing the squamous cell carcinoma group 
(n = 70) with the adenocarcinoma group (n = 174), there 
were no significant differences with respect to the -1195 
genotype distribution: -1195 AA, 55.7% vs 57.5%; -1195 
AG, 37.1% vs 33.9% and -1195 GG, 7.2% vs 8.6% (P = 
0.97). For the -765 genotypes no differences in distribution 
between the squamous cell carcinoma and adenocarcinoma 
groups were found: -765 GG, 69.5% vs 68.7%; -765 GC, 
27.1% vs 28.2% and -765 CC, 3.4% vs 3.1% (P = 0.95).
Table 3 shows the results of  a comparison of  the 
distribution of  the COX-2 -765 and -1195 haplotypes, 
according to the type of  tumor. Only one significant 
difference was found, the GG/GG haplotype was 
present more often in the esophageal adenocarcinoma 
group than in the control group (OR = 3.45, 95% 
CI = 1.24-9.58). However, the number of  individuals 
Table 1  Characteristics of patients with oesophageal carcinoma and controls  n (%)
Characteristics Patients with oesophageal carcinoma Controls
Total Adeno carcinoma Squamous cell carcinoma Mixed
n            252 174 (69.0) 70 (27.8) 8 (3.2) 240
Age (yr; mean ± SD) 64.3 ± 10.8 64.7 ± 11.0 62.7 ± 10.2 69.9 ± 8.0 64.6 ± 10.9
Gender   
   Female   51 (20.2)   24 (13.8) 26 (37.1)   1 (12.5)   51 (21.2)
   Male 201 (79.8) 150 (86.2) 44 (62.9)   7 (87.5) 189 (78.8)
Table 3  COX-2  haplotype distribution and corresponding ORs in patients with oesophageal adenocarcinoma or squamous cell 
carcinoma carcinoma versus  controls
Haplotype COX-2 Adenocarcinoma Squamous cell carcinoma Controls 
n  = 236 (%)
n  = 163 (%) OR (95% CI) n  = 59 (%) OR (95% CI)
AG/AG 59 (36.2) Reference 18 (30.5) Reference 94 (39.8)
AG/AC 29 (17.8) 0.87 (0.50-1.52) 12 (20.3) 1.18 (0.53-2.64) 53 (22.4)
AC/AC 5 (3.1) 1.33 (0.39-4.55) 2 (3.4) 1.74 (0.33-9.32) 6 (2.5)
GC/AC                  0 (0) -                  0 (0) -                  0 (0)
GG/AC 17 (10.4) 1.29 (0.63-2.64) 4 (6.8) 0.99 (0.31-3.24)                21 (8.9)
GG/AG 40 (24.5) 1.14 (0.68-1.91) 19 (32.2) 1.77 (0.86-3.66) 56 (23.7)
GG/GG                13 (8.0) 3.45 (1.24-9.58) 4 (6.8) 3.48 (0.89-13.6) 6 (2.5)
Table 2  Distribution of the COX-2 -1195A→G and -765 G→C genotypes and corresponding ORs in patients with oesophageal 
adenocarcinoma or squamous cell carcinoma versus  controls
Genotype COX-2 Adenocarcinoma Squamous cell carcinoma Controls 
n  (%)n  (%) OR (95% CI) n  (%) OR (95% CI)
-1195A→G
   -1195A/-1195A 100 (58) Reference 39 (56) Reference 154 (64)
   -1195G/-1195A   59 (34) 1.13 (0.75-1.73) 26 (37) 1.28 (0.73-2.26)   80 (33)
   -1195G/-1195G 15 (9) 3.85 (1.45-10.3) 5 (7) 3.29 (0.95-11.4)   6 (3)
   Total                174                 70                240
-765 G→C1
   -765G/-765G 112 (69) Reference 41 (69) Reference 157 (66)
   -765G/-765C   46 (28) 0.88 (0.57-1.37) 16 (27) 0.84 (0.44-1.60)   73 (31)
   -765C/-765C   5 (3) 1.17 (0.35-3.92) 2 (3) 1.28 (0.25-6.56)   6 (3)
   Total                163                 59                236
1In both the cases and control group, there are some missing data because of unsuccessful PCR; OR: Odds ratio; CI: Confidence interval.
Kristinsson JO et al . COX-2  polymorphisms and esophageal carcinoma                                                          3495
www.wjgnet.com
present in these subgroups was very small (n = 13 vs n 
= 6, respectively). The same trend was observed in the 
squamous cell carcinoma group, however, statistical 
significance was not reached. 
DISCUSSION
The -1195 GG genotype was present more often in 
patients with esophageal carcinoma than in controls. 
This is in contrast to the findings of  Zhang et al [12] 
who identified the -1195 AA genotype as a risk factor 
for esophageal carcinoma. It is commonly reported 
that COX-2 expression is higher in cancerous tissue, 
because high COX-2 expression contributes to and 
sustains inflammatory and pre-cancerous processes[4,6]. 
Zhang et al [12] also concluded that COX-2 mRNA 
expression in -1195 AA genotypes was much higher 
than the mRNA expression in tissues of  patients with 
the -1195 GG genotype. Our findings now suggest 
that the COX-2 -1195 polymorphism has the opposite 
effect on esophageal carcinoma risk in Caucasians, as 
compared to Chinese patients. However, two limitations 
must be noted: firstly, we did not measure whether the 
COX-2 mRNA expression in -1195 AA genotypes was 
highest in our group of  Caucasian patients, similar to the 
findings of  Zhang et al[12] in Chinese patients. Secondly, 
there is a difference between our study population 
and that of  Zhang et al[12]; the majority of  our patients 
had adenocarcinoma (69%) and the minority suffered 
from squamous cell carcinoma (28%), whereas the 
Chinese patients in the study by Zhang et al[12] all had 
squamous cell carcinoma. In China, esophageal squamous 
cell carcinoma is significantly more common than 
adenocarcinoma, as it is mainly caused by lifestyle factors 
such as drinking hot beverages and eating spicy foods, 
whereas adenocarcinoma is associated with acid reflux as 
a result of  the Western lifestyle[1]. In our patient group, we 
found no differences in the distribution of  both COX-2 
polymorphisms between patients with adenocarcinoma 
and squamous cell carcinoma, which suggests that the 
differences found when compared to the results of  Zhang 
et al[12] could be assigned merely to racial differences rather 
than to differences in the type of  tumor. 
Another indication that racial differences in the study 
populations may explain the apparent contradictory 
results is obtained by comparing the distribution of  
the COX-2 polymorphisms in the Chinese and Dutch 
control populations. The genotype frequencies found 
in our Dutch controls for the -765 G→C and -1195 A
→G polymorphisms were: 66.5% GG, 30.9% GC, 2.9% 
CC and 64.2% AA, 33.3% GA, 2.5% GG, respectively. 
Zhang et al[12] in a Chinese population reported genotype 
frequencies of  95.7% GG, 4.3% GC, 0% CC and 24.1% 
AA, 53.4% GA and 22.5% GG, respectively. Tan et al in 
Chinese controls more recently reported approximately 
the same genotype frequencies as Zhang et al: 95.2% 
GG, 4.8% GC, 0% CC and 23.7% AA, 53.2% GA and 
23.1% GG, respectively[15].
On the other hand, our control group data on the 
COX-2 -765 genotype were in good agreement with other 
European control data recently reported from Denmark, 
being 73.2%, 24.8% and 2.0% for -765 GG, GC and 
CC genotypes, respectively[16]. In addition, the COX-2 
polymorphism data in our patients are very similar to 
the recently reported COX-2 -765 and -1195 genotype 
distributions in Dutch esophageal adenocarcinoma 
patients by Moons et al[17], except for the -1195 GG 
genotype, which was present in 8.0% of  our patients vs 
only 2.0% in the patients in the study by Moons et al[17].
The distribution of  the -765 genotypes in the control 
group was not found to be significantly different when 
compared to the esophageal carcinoma group, whereas 
Moons et al[17] reported a significantly different -765 
CC genotype distribution between a Dutch esophageal 
carcinoma group (n = 140) and a Barrett’s esophagus (n 
= 255) or reflux esophagitis (n = 240) patient group. It 
should be noted, however, that the number of  -765 CC 
genotype individuals in these patient groups was very low, 
being seven, four and zero individuals, respectively[17]. 
Two main reasons for the difference in results between 
the two Dutch studies are as follows: firstly, our study was 
performed on a larger patient population than the study 
by Moons et al[17] (252 vs 140 patients), and secondly in our 
study, similar to the study by Zhang et al[12], a comparison 
between patients with esophageal cancer and healthy 
controls was made, in contrast to the study by Moons 
et al[17] where patients with Barrett’s esophagus or reflux 
esophagitis, both of  which are at risk for esophagus 
carcinoma, were used for comparison.
Analyzing the COX-2 haplotypes showed that the 
GG/GG haplotype was present more often in the 
esophageal carcinoma group, which again is not in 
accordance with the results of  Zhang et al[12] and Moons 
et al[17], who both found that the CA containing haplotypes 
carried the highest risk. Since the results of  Zhang et al[12] 
and Moons et al[17] on different types of  tumors (squamous 
cell carcinoma vs adenocarcinoma, respectively) are 
very similar, and more or less contradict our results, it 
was of  interest to compare the haplotype distribution 
between our patients with squamous cell carcinoma vs 
adenocarcinoma. However, no significant differences were 
found. 
In conclusion, the presence of  the COX-2 -1195 GG 
genotype and of  the GG/GG haplotype may result in a 
higher risk of  developing esophageal adenocarcinoma 
and possibly also squamous cell carcinoma. 
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